HANGZHOU, China, July 31, 2026 /PRNewswire/ — CellOrigin, a biotechnology company focused on next-generation in vivo and in vitro cell therapy technologies, has announced two major progresses in both research and strategic partnership. At the 2026 ASCO Annual Meeting, CellOrigin’s scientific co-founder’s team presented two new studies on solid tumor cell therapy. The first, CAR-MixTM multicellular [...]
CellOrigin Unveils Two Novel Solid-Tumor Cell Therapy Candidates at ASCO 2026, Partners with Walvax for In Vivo CAR Clinical Trial
